Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000155106 | SCV000204792 | uncertain significance | not specified | 2018-03-21 | criteria provided, single submitter | clinical testing | The p.Ala1503Thr variant in ADGRV1 has been previously identified by our laborat ory in two individuals with hearing loss; however a variant affecting the remain ing copy of ADGRV1 was not identified in either individual. This variant has bee n identified in 56/126586 European chromosomes by the Genome Aggregation Databas e (gnomAD, http://gnomad.broadinstitute.org/; dbSNP rs201391886) and is reported in ClinVar (Variation ID: 110040). Although this variant has been seen in the g eneral population, its frequency is not high enough to rule out a pathogenic rol e. Computational prediction tools and conservation analysis do not provide stron g support for or against an impact to the protein. In summary, the clinical sign ificance of the p.Ala1503Thr variant is uncertain. ACMG/AMP Criteria applied: No ne. |
Eurofins Ntd Llc |
RCV000488366 | SCV000227849 | uncertain significance | not provided | 2014-11-14 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000488366 | SCV000575431 | uncertain significance | not provided | 2016-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000488366 | SCV001212546 | likely benign | not provided | 2024-09-16 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001151340 | SCV001312461 | uncertain significance | Usher syndrome type 2C | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
Gene |
RCV000488366 | SCV002039056 | uncertain significance | not provided | 2024-07-10 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002483173 | SCV002776987 | uncertain significance | Usher syndrome type 2C; Febrile seizures, familial, 4 | 2022-01-21 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000488366 | SCV004227096 | uncertain significance | not provided | 2022-04-13 | criteria provided, single submitter | clinical testing | PM2_supporting |
Diagnostic Laboratory, |
RCV000488366 | SCV001740668 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000488366 | SCV001976135 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Institute of Human Genetics, |
RCV004815186 | SCV005072311 | uncertain significance | Retinal dystrophy | 2022-01-01 | no assertion criteria provided | clinical testing |